Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT : E£1,472 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments EBIT?

Egyptian International Pharmaceutical Investments's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was E£353 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was E£1,472 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Dec. 2023 was 13.72%. Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 20.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 14.12%.

Egyptian International Pharmaceutical Investments EBIT Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments EBIT Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

704.87

790.42

1,000.17

1,471.78

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															350.46	293.38	523.09	302.05	353.26

Competitive Comparison of Egyptian International Pharmaceutical Investments's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's EV-to-EBIT falls into.

Egyptian International Pharmaceutical Investments EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£1,472 Mil.

Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	1520.884 * ( 1 - 22.09% )	/	( (8532.064	+	8741.988)	/ 2 )
=	1184.9207244	/	8637.026
=	13.72 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9742.746	-	544.803	-	( 665.879	-	max(0, 3017.238	-	5472.206	+	665.879	))
=	8532.064

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9978.783	-	560.997	-	( 675.798	-	max(0, 2830.735	-	5486.11	+	675.798	))
=	8741.988

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1413.04	/	( ( (3828.497 + max(2856.438, 0))	+	(4023.88 + max(2771.595, 0)) )	/	2 )
=	1413.04	/	( ( 6684.935	+	6795.475 )	/	2 )
=	1413.04	/	6740.205
=	20.96 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1252.078	+	2235.195	+	127.281)	-	(544.803	+	0	+	213.313)
=	2856.438

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1153.421	+	2242.396	+	158.991)	-	(560.997	+	0	+	222.216)
=	2771.595

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	1471.78	/	10423.653
	=	14.12 %

Egyptian International Pharmaceutical Investments EBIT Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.